Company intelligence / Profile preview

AMS BioteQ

Ownership: Private
Employees: ~49
Development stage: Preclinical

Overview

AMS BioteQ has demonstrated preclinical efficacy of its lead antiviral compounds YUAN‑01 and YUAN‑03 against SARS-CoV‑2 in cell-based assays, with YUAN‑03 showing strong viral inhibition. The company’s wound dressing products combining natural antimicrobials are commercially available. Additional pipeline candidates target dengue, Zika, and avian influenza viruses[3].

Therapeutic areas: Infectious Diseases
Modalities: Natural products (fungal-derived compounds)Small molecules (antiviral/antibacterial agents)Medical materials (wound dressings with antimicrobial properties)
Industry: Biotech

Drug pipeline

3 assets

AMS-2140

Preclinical

2 more assets in the full pipeline.

Partnerships

National Taiwan University College of Medicine[3]

Beyond the preview

Go deeper on AMS BioteQ.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMS BioteQ.